Publications

5600 Results

North American Patterns of Care in Clinical Stage I Testicular Cancer. Secondary Data Use Project for SWOG S1823

Authors
A Morin Coulombe;S Colby;J King;M Neuhouser;B Arun;S Daneshman;A Harzstark;K Arnold;C Nichols;L Nappi
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), poster; J Clin Oncol 42, 2024 (suppl 4; abstr 509)
Year
2024
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S1823

Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL

Authors
J Wolfson;A Grimes;M Nuno;C Kerber;S Ramakrishnan;M Beauchemin;D Dickens;J Levine;M Roth;M Scialla;W Woods;S Vargas;K Boayue;G Chang;W Stock;D Hershman;E Curran;A Advani;K O'Dwyer;S Luger;J Liu;D Freyer;L Sung;S Parsons
Journal / Conference
JCO Oncology Practice Apr;20(4):491-502
Year
2024
Research Committee(s)
Cancer Care Delivery
PMID
PMID38252911
PMC
PMC11085951

SWOG S2303: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS = 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Authors
A Saeed;S Colby;P Oberstein;D Duda;R Agarwal;C Figeroa-Moseley;R Vaidya;J Unger;K Guthrie;F Rocha;M Senthil;R Safyan;Z Wainberg;S Iqbal;EG Chiorean;PA Philip
Journal / Conference
J Clin Oncol 42, 2024 (suppl 3; abstr TPS430); ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA), TIP, poster
Year
2024
Research Committee(s)
Gastrointestinal

Postoperative Complications Following Neoadjuvant Therapy and Surgery in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501)

Authors
R Snyder;S Ahmad;D Segovia;T Zemla;Q Shi;E O'Reilly;J Herman;M Katz
Journal / Conference
ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA); J Clin Oncol 42, 2024 (suppl 3; abstr 664), poster
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021501

Chemotherapy Dose Density is Prognostic for Patients with Resectable Pancreas Cancer: A Secondary Analysis of SWOG S1505

Authors
SH Patel;S Colby;D Sohal;K Guthrie;L Kachnic;E Chiorean;A Lowy;F Rocha;PA Philip;S Ahmad
Journal / Conference
Society of Surgical Oncology (March 20-23, 2024, Atlanta, GA) oral
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
S1505

Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505

Authors
J Cloyd;S Colby;K Guthrie;A Lowy;E Chiorean;P Philip;D Sohal;S Ahmad
Journal / Conference
Journal of the National Comprehensive Cancer Network Apr 29:1-6
Year
2024
Research Committee(s)
Gastrointestinal
PMID
PMID38688309
Study Number(s)
S1505

Body Composition Measurements and Clinical Outcomes in Patients with Resectable Pancreatic Adenocarcinoma – Analysis from SWOG S1505

Authors
D Sohal;K Guthrie;R Boutin;L Lenchik;J Kim;S Beg;A Wang-Gillam;J Wade;E Chiorean;S Ahmad;A Lowy;P Philip;V Chang
Journal / Conference
Journal of Gastrointestinal Surgery Mar;28(3):232-235
Year
2024
Research Committee(s)
Gastrointestinal
PMID
38445914
Study Number(s)
S1505

Adjuvant everolimus in patients with completely resected very high-risk renal cell cancer and clear cell histology: results from the phase III placebo-controlled SWOG S0931 (EVEREST) trial

Authors
P Lara;C Tangen;E Heath;S Gulati;M Stein;M Meng;A Alva;S Pal;I Puzanov;J Clark;T Choueiri;N Agarwal;R Uzzo;N Haas;T Synold;M Plets;U Vaishampayan;B Shuch;S Lerner;I Thompson;C Ryan
Journal / Conference
European Urology May 28:S0302-2838(24)02383-2
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID38811313
Study Number(s)
S0931

A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis

Authors
P Hagen;S Sidana;T Parker;A Hoering;V Sanchorawala;J Zonder;T Kourelis;A DSouza;H Landau;A Rosenthal;S Ailawadhi;R Orlowski;B Walker
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS7575)
Year
2024
Research Committee(s)
Myeloma
Study Number(s)
S2213

Effects of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes: Primary Results from the Randomized Phase III Double-Blind Clinical Trial (S1600)

Authors
J Hamilton-Reeves;J Unger;J Holzbeierlein;DL Lew;J Mark;S Daneshmand;J Kukreja;E Lee;W Tabayoyong;D Hershman;M Fisch;NL Henry
Journal / Conference
J Clin Oncol 42, 2024 (suppl 16; abstr 4501); ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral presentation, oral abstract session
Year
2024
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S1600